Daniel Shao-Weng Tan

9.3k total citations · 2 hit papers
173 papers, 4.8k citations indexed

About

Daniel Shao-Weng Tan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daniel Shao-Weng Tan has authored 173 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Pulmonary and Respiratory Medicine, 100 papers in Oncology and 49 papers in Molecular Biology. Recurrent topics in Daniel Shao-Weng Tan's work include Lung Cancer Treatments and Mutations (113 papers), Lung Cancer Research Studies (39 papers) and Cancer Genomics and Diagnostics (38 papers). Daniel Shao-Weng Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (113 papers), Lung Cancer Research Studies (39 papers) and Cancer Genomics and Diagnostics (38 papers). Daniel Shao-Weng Tan collaborates with scholars based in Singapore, United States and Switzerland. Daniel Shao-Weng Tan's co-authors include Wan‐Teck Lim, Chwee Teck Lim, Jongyoon Han, Ali Asgar S. Bhagat, Majid Ebrahimi Warkiani, Ross A. Soo, Bee Luan Khoo, Soo Chin Lee, Han Wei Hou and Zirui Li and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel Shao-Weng Tan

168 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Isolation and retrieval of circulating tumor cells using centrifugal forces

2013 595 citations Ross A. Soo, Daniel Shao-Weng Tan et al. profile →
Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells

2013 472 citations Daniel Shao-Weng Tan, Wan‐Teck Lim et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Shao-Weng Tan Singapore	34	2.5k	2.0k	1.5k	1.2k	1.0k	173	4.8k
Daniel M. Aebersold Switzerland	34	1.2k 0.5×	1.4k 0.7×	1.4k 0.9×	316 0.3×	1.2k 1.1×	225	4.6k
Johannes H.A.M. Kaanders Netherlands	50	1.7k 0.7×	2.2k 1.1×	1.9k 1.2×	634 0.5×	2.5k 2.4×	177	7.4k
Maximilian Niyazi Germany	40	928 0.4×	2.3k 1.1×	1.1k 0.7×	419 0.4×	1.2k 1.2×	270	6.2k
Steven J. Chmura United States	39	2.5k 1.0×	2.5k 1.3×	1.0k 0.7×	307 0.3×	868 0.8×	172	6.0k
François‐Clément Bidard France	47	5.0k 2.0×	2.4k 1.2×	2.0k 1.3×	945 0.8×	4.5k 4.4×	220	7.8k
Mark De Ridder Belgium	39	1.4k 0.6×	2.1k 1.1×	715 0.5×	592 0.5×	798 0.8×	199	5.2k
Esther G.C. Troost Germany	40	794 0.3×	2.3k 1.1×	472 0.3×	645 0.6×	911 0.9×	199	4.8k
Katherine A. Vallis United Kingdom	40	1.4k 0.6×	1.0k 0.5×	1.4k 0.9×	607 0.5×	864 0.8×	154	4.6k
Andrei Iagaru United States	41	1.3k 0.5×	2.1k 1.1×	439 0.3×	397 0.3×	402 0.4×	253	5.0k
Matthew Krebs United Kingdom	28	4.0k 1.6×	1.9k 0.9×	1.4k 0.9×	796 0.7×	2.2k 2.1×	156	5.4k

Countries citing papers authored by Daniel Shao-Weng Tan

Since Specialization

Citations

This map shows the geographic impact of Daniel Shao-Weng Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Shao-Weng Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Shao-Weng Tan more than expected).

Fields of papers citing papers by Daniel Shao-Weng Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Shao-Weng Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Shao-Weng Tan. The network helps show where Daniel Shao-Weng Tan may publish in the future.

Co-authorship network of co-authors of Daniel Shao-Weng Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Shao-Weng Tan. A scholar is included among the top collaborators of Daniel Shao-Weng Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Shao-Weng Tan. Daniel Shao-Weng Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tan, Daniel Shao-Weng, et al.. (2025). Biomolecular condensate microstructure is invariant to sequence-encoded molecular and macroscopic properties. Soft Matter. 21(45). 8635–8654.

Foote, Michael B., Jingjing Li, Daniel Shao-Weng Tan, et al.. (2025). 925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation. Annals of Oncology. 36. S567–S568.

Tan, Daniel Shao-Weng, et al.. (2025). Prediction of Small-Molecule Partitioning into Biomolecular Condensates from Simulation. JACS Au. 5(7). 3125–3139. 2 indexed citations

Schram, Alison M., Gilberto Lopes, Elisa Fontana, et al.. (2024). 691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation. Annals of Oncology. 35. S535–S536. 2 indexed citations

Tay, Timothy Kwang Yong, Enya H.W. Ong, Michael Fehlings, et al.. (2024). Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer. European Thyroid Journal. 13(1). 8 indexed citations

Le, Xiuning, Nicolas Girard, Hye Ryun Kim, et al.. (2024). PL04.03 Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study. Journal of Thoracic Oncology. 19(10). S4–S4. 6 indexed citations

Loong, Herbert H., Gennaro Daniele, Ticiana Leal, et al.. (2023). 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088. Annals of Oncology. 34. S761–S762. 4 indexed citations

Negrão, Marcelo V., Philippe A. Cassier, Benjamin Solomon, et al.. (2023). MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors. Journal of Thoracic Oncology. 18(11). S117–S118. 16 indexed citations

Drilon, Alexander, Lin Shen, François Doz, et al.. (2023). 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer. Annals of Oncology. 34. S470–S470. 2 indexed citations

10.

Jazieh, Abdul Rahman, Cem Önal, Daniel Shao-Weng Tan, et al.. (2022). Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study. Therapeutic Advances in Medical Oncology. 14. 4287534752–4287534752. 4 indexed citations

11.

Bauer, Sebastian, George D. Demetri, Ensar Halilovic, et al.. (2021). Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. British Journal of Cancer. 125(5). 687–698. 25 indexed citations

12.

Wirth, Lori J., Eric J. Sherman, Bruce Robinson, et al.. (2021). O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer. Annals of Oncology. 32. S289–S289. 1 indexed citations

13.

Sullivan, Ryan J., Jeffrey S. Weber, Sapna P. Patel, et al.. (2020). A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors. Clinical Cancer Research. 26(19). 5102–5112. 30 indexed citations

14.

McDermott, Ray, Cornelis M. van Tilburg, Anna F. Farago, et al.. (2020). 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. Annals of Oncology. 31. S1101–S1102. 13 indexed citations

15.

Tan, Daniel Shao-Weng, M-J. Ahn, Herbert H. Loong, et al.. (2020). 299MO Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC. Annals of Oncology. 31. S1358–S1359. 2 indexed citations

16.

Drilon, Alexander, Víctor Moreno, Jyoti D. Patel, et al.. (2020). 1289P Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Annals of Oncology. 31. S834–S834. 5 indexed citations

17.

Tan, E.H., Wan‐Teck Lim, Mei‐Kim Ang, et al.. (2018). Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore. Annals of Oncology. 29. ix161–ix161. 5 indexed citations

18.

Tan, Daniel Shao-Weng, Dae Ho Lee, Ross A. Soo, et al.. (2017). P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1264–S1265. 6 indexed citations

19.

Castro, Gilberto de, Daniel Shao-Weng Tan, Lucio Crinò, et al.. (2017). PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). Journal of Thoracic Oncology. 12(1). S7–S7. 8 indexed citations

20.

Gainor, Justin F., Daniel Shao-Weng Tan, Benjamin Solomon, et al.. (2015). Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clinical Cancer Research. 21(12). 2745–2752. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact